Father's AI Research DFNB16

STRC c.4976 AC

I asked AI what that means. Came up with a variant pathogenicity analysis and a new hypothesis.

Michael is 4. He doesn't hear well. Two broken copies of the STRC gene. One confirmed pathogenic. The other: "Variant of Uncertain Significance." Three words that block him from gene therapy trials.

I'm not a geneticist. I build websites, shoot video, and do AI education. I have an AI agent (OpenClaw, powered by Claude Opus 4.6) running on my laptop. It searches databases, downloads protein structures, runs analysis. I ask questions from my phone while Michael plays next to me.

One question led to reclassification evidence. Then conservation analysis. Then a hypothesis about fitting the gene into a single therapy vector. Then six structural experiments. Then three emails to the scientists who pioneered this research. One responded overnight. By day three, we had a new hypothesis: a self-dosing gene therapy where sound itself activates the treatment, backed by an ODE model showing therapeutic protein levels in 13 hours.

Science shouldn't be locked behind jargon. There's a podcast and a video below (both AI-generated) for anyone who'd rather listen than scroll through protein structures.

Listen to podcast
AI-generated · NotebookLM
Watch video overview
AI-generated · NotebookLM
Built with OpenClaw (free, open source) + Claude Opus 4.6 (API, ~$50-100) + AlphaFold + AlphaFold 3 + AlphaMissense + UniProt + Ensembl (all free)
Egor and Michael

Egor and Michael, Hong Kong

AlphaMissense
0.9016
Likely Pathogenic
AlphaFold pLDDT
95.69
Very high confidence
REVEL Score
0.65
Predicted deleterious
Conservation
9/9
Mammals conserved

Explore the Research

Part 1

Reclassification Evidence

Computational evidence supporting VUS to Likely Pathogenic reclassification for NM_153700.2:c.4976A>C p.(Glu1659Ala)

AlphaMissense Conservation Structure3D ACMG
Part 2

Research Hypotheses

Computational hypotheses for accelerating STRC gene therapy. These require experimental validation.

Mini-STRC Prime Editing Delivery +4 more
Part 3

How I Did This

Step-by-step methodology so anyone can reproduce these results

Methods Tools Reproducibility

Treatment Window

CRITICAL

Gene therapy for DFNB16 is time-sensitive. Mouse data from Iranfar et al. (2026) defines a critical developmental window where intervention works, and when it closes.

Mouse data (Iranfar 2026)

Dual-AAV STRC was injected into Strc-/- mouse cochleae via round window at different postnatal ages (P1 through P14-18). DPOAE and ABR measured 4 weeks post-injection.

P1-P5
P7-P9
P14+
Birth Full recovery Declining No recovery
~60%
OHC transduction (P1-P5 injection)
WT-level
ABR/DPOAE thresholds restored
0%
Recovery when injected at P14+

Translating to humans

The mouse therapeutic window (P1-P5) corresponds roughly to the third trimester through early postnatal period in humans, when the cochlea is still maturing. However, human cochlear development is largely complete by birth, which complicates direct translation.

Parameter Mouse Human (estimated)
Treatment window P1-P5 Prenatal - early postnatal?
Cochlea length ~3.5 mm ~35 mm
Dual-AAV co-transduction ~60% ~6% (stochastic model)
Hearing loss pattern Stable (mild-moderate) Stable (mild-moderate)

What this means

DFNB16 hearing loss is stable, not progressive. OHCs are present but lack stereocilin at their stereocilia tips. The structural damage (missing horizontal top connectors and tectorial membrane attachment crowns) occurs during cochlear maturation.

The good news: because DFNB16 is non-degenerative (OHCs survive), there may be a wider intervention window than degenerative conditions. The cells are there; they just need the protein. The mouse P5 cutoff may reflect when stereocilia structure becomes irreversibly disorganized without STRC, not cell death.

The open question: can stereocilia reorganize if stereocilin is provided after the developmental window? In mice, injection at P7-P9 still achieved some transduction but no functional recovery. Understanding whether this is a structural rigidity problem or an expression timing problem is crucial for human translation.

Key uncertainty: The mouse P1-P5 window cannot be directly mapped to human developmental stages. Human cochlear maturation is largely complete by week 20 of gestation. Whether postnatal gene therapy can still rescue function in humans depends on how long OHC stereocilia retain structural plasticity after birth. Early intervention (ideally within the first year) is likely critical.

Iranfar et al. (2026) "Dual AAV gene therapy achieves recovery of hearing and auditory processing in a DFNB16 mouse model." Clin Transl Med.

Gadenstaetter et al. (2024) "Inner ear gene therapy: An overview from bench to bedside." Mol Diagn Ther.